← back to search

Howard M. Stern

University of Alabama at Birmingham · US
Area of research
Oncology · Molecular Biology
Research interest
Research interests include Medicine, Cancer research, Biology, Cancer, Breast cancer, and Gene.
h-index
citations
3,213
works
11
NIH funding
primary concept
email

Recent publications

Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma
Blood 2017cited by 280position: middledoi
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
Nature 2016cited by 857position: middledoi
PTEN Loss Is Associated with Worse Outcome in <i>HER2</i> -Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance
Clinical Cancer Research 2015cited by 68position: firstdoi
Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes
Cancer Research 2014cited by 162position: middledoi
Integrated exome and transcriptome sequencing reveals ZAK isoform usage in gastric cancer
Nature Communications 2014cited by 96position: middledoi
Oncogenic ERBB3 Mutations in Human Cancers
Cancer Cell 2013cited by 347position: middledoi
Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)
Breast Cancer Research and Treatment 2013cited by 81position: middledoi
High Heregulin Expression Is Associated with Activated HER3 and May Define an Actionable Biomarker in Patients with Squamous Cell Carcinomas of the Head and Neck
PLoS ONE 2013cited by 70position: middledoi
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer
Nature Genetics 2012cited by 1,095position: middledoi
Analysis of Fcγ Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients
Clinical Cancer Research 2012cited by 111position: middledoi
Phase Ib Study of Drozitumab Combined With First-Line mFOLFOX6 Plus Bevacizumab in Patients with Metastatic Colorectal Cancer
Cancer Investigation 2012cited by 46position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Dennis J. Slamon · APLA Health3 papers (2012–2015)John R. Mackey · BC Cancer Agency2 papers (2012–2015)Lukas C. Amler · Indiana University – Purdue University Indianapolis2 papers (2012–2013)John Crown · Lublin Oncology Center2 papers (2012–2015)Rajiv Raja · GlaxoSmithKline (United States)2 papers (2012–2013)Michael F. Press · University of Southern California2 papers (2013–2015)Valerie Bée · University of Alabama at Birmingham2 papers (2012–2015) · 2 papers (2013–2015)Mark Douglas · Westmead Hospital2 papers (2016–2017)Nicholas J. Robert · AIR Worldwide (United States)2 papers (2012–2015)Marc Buyse · University College London2 papers (2012–2013)Somasekar Seshagiri · University of Alabama at Birmingham2 papers (2012–2014)Miguel Martín · Spanish Ovarian Cancer Research Group2 papers (2012–2015)W. Eiermann · Technical University of Munich2 papers (2012–2015)Tadeusz Pieńkowski · Radom College2 papers (2012–2015)Wilma L. Lingle · Mayo Clinic in Arizona1 papers (2013–2013)Jon C. Aster · Harvard University1 papers (2017–2017)Soonmyung Paik · Yonsei University1 papers (2013–2013)Caio M. Rocha Lima · Atrium Health Wake Forest Baptist1 papers (2012–2012)Emmanuel Quinaux · Centre Jean Bernard1 papers (2012–2012)